Chlorpyrifos has undergone dramatic changes in its market trajectory, from a blockbuster proprietary molecule to a globally traded generic active ingredient. AgriBusiness Global spoke with Ram ...
In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...
The generic product is now available nationwide in strengths of 0.3mg, 0.45mg, 0.625mg, 0.9mg, and 1.25mg. The Food and Drug Administration (FDA) has approved the first generic version of Premarin ® ...
Pacira BioSciences faces significant risk as generic challenges threaten Exparel, its flagship product responsible for 78% of 2024 revenue. PCRX's complex formulation, robust patent estate, and ...
This annual observance highlights the importance of generic medicines in providing affordable, effective and accessible healthcare to Filipinos. It was held under the theme “Ginhawang Generics, Ramdam ...
President Trump has delayed imposing tariffs on pharmaceuticals to allow for more negotiations with drug companies. (Francis Chung/Bloomberg News) The Trump administration says it doesn't plan to ...
President Trump said he expects to reach pricing deals with more drug companies following the Pfizer announcement. Photo: Win McNamee/Getty Images WASHINGTON—The Trump administration said it isn’t ...
The Food and Drug Administration on Tuesday quietly approved a generic form of mifepristone, one of the two medications used in most U.S. abortions. That makes the drug, from the company Evita ...
The decision enraged opponents of abortion, who have been pressuring the Trump administration to restrict access to abortion medication. By Pam Belluck The Food and Drug Administration has approved a ...
The U.S. Securities and Exchange Commission (SEC) on Wednesday approved a set of rules for exchanges to list exchange-traded products (ETPs) holding spot commodities, including cryptocurrencies, ...
AbbVie settles with generic Rinvoq hopefuls, shielding the immunology med's US stronghold until 2037
With Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback